Pharmacodynamics of vancomycin for CoNS infection: Experimental basis for optimal use of vancomycin in neonates

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 992-1002

  Ramos Martin V ^a   Johnson, A ^a   Livermore, J ^a   McEntee, L ^a   Goodwin, J ^a   Whalley, S ^a   Docobo Perez F ^b   Felton, T W ^c   Zhao, W ^d   Jacqz Aigrain, E ^d   Sharland, M ^e   Turner, M A ^a   Hope, W W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF SEVILLE   (Spain)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CATHETER INFECTION; CELL KILLING; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; HOLLOW FIBER; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEW ZEALAND WHITE (RABBIT); NEWBORN; NEWBORN INFECTION; NEWBORN SEPSIS; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; RISK ASSESSMENT; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS EPIDERMIDIS; ALGORITHM; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; NEONATAL SEPSIS; RABBIT; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; THEORETICAL MODEL;

ALGORITHMS; ANIMALS; ANIMALS, NEWBORN; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; MONTE CARLO METHOD; NEONATAL SEPSIS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; VANCOMYCIN;

EID: 84962249098     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv451     Document Type: Article

References (32)

1. Levit O, Bhandari V, Li F-Y et al. Clinical and laboratory factors that predict death in very low birth weight infants presenting with late-onset sepsis. Pediatr Infect Dis J 2014; 33: 143-6.
2. Stoll BJ, Hansen NI, Bell EF et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126: 443-56.
3. Hornik CP, Fort P, Clark RH et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev 2012; 88 Suppl 2: S69-74.
4. Vergnano S, Menson E, Kennea N et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011; 96: F9-14.
5. Stoll BJ, Gordon T, Korones SB et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 63-71.
6. Stoll BJ, Hansen N, Fanaroff AA et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110: 285-91.
7. Wisplinghoff H, Rosato AE, Enright MC et al. Related clones containing SCC mec type IV predominate among clinically significant Staphylococcus epidermidis isolates. Antimicrob Agents Chemother 2003; 47: 3574-9.
8. Milstone AM, Reich NG, Advani S et al. Catheterdwell time and CLABSIs in neonates with PICCs: a multicenter cohort study. Pediatrics 2013; 132: e1609-15.
9. Karlowicz MG, Furigay PJ, Croitoru DP et al. Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia. Pediatr Infect Dis J 2002; 21: 22-7.
10. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006; 19: 290-7.
11. Mitha A, Foix-L'Hélias L, Arnaud C et al. Neonatal infection and 5-year neurodevelopmental outcome of very preterm infants. Pediatrics 2013; 132: e372-80.
12. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
13. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2015. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf.
14. Nicasio AM, Bulitta JB, Lodise TP et al. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother 2012; 56: 682-6.
15. Felton TW, Goodwin J, O'Connor L et al. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013; 57: 5811-9.
16. Seay RE, Brundage RC, Jensen PD et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169-75.
17. Nicolau DP, Freeman CD, Nightingale CH et al. Pharmacokinetics of minocycline and vancomycin in rabbits. Lab Anim Sci 1993; 43: 222-5.
18. Ahmed A, Jafri H, Lutsar I et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin-and cephalosporin-resistant pneumococcalmeningitis. Antimicrob Agents Chemother 1999; 43: 876-81.
19. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
20. Gumbo T, Louie A, Deziel MR et al. Selection of amoxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-51.
21. Sharland M, Andrew Cant E, Davies G et al. OSH Manual of Childhood Infections: The Blue Book. 3rd edn. London: Oxford University Press, 2011.
22. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. 2009. Biomedical Simulations Resource, CA, USA.
23. Tam VH, Louie A, Deziel MR et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 2007; 51: 744-7.
24. Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52: 616-22.
25. Knudsen JD, Fuursted K, Raber S et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247-54.
26. Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
27. Butterfield JM, Patel N, Pai MP et al. Refining vancomycin protein binding estimates: Identification of clinical factors that influence protein binding. Antimicrob Agents Chemother 2011; 55: 4277-82.
28. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
29. Le J, Bradley JS, Murray W et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J 2013; 32: e155-63.
30. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J 2013; 32: 1077-9.
31. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52.
32. British National Formulary for Children 2014-2015. 2014; 289-90. http://www.evidence.nhs.uk/formulary/bnfc/current/5-infections/51-antibacterial-drugs/517-some-other-antibacterials/vancomycin-andteicoplanin/vancomycin.